![Mads Dalsgaard](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Cargos activos de Mads Dalsgaard
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
AptaTargets SL
![]() AptaTargets SL Pharmaceuticals: MajorHealth Technology AptaTargets SL is a biopharmaceutical company based in Madrid, Spain that focuses on developing therapeutic applications based on aptamer technology. The Spanish company is currently developing aptoll, an immune modulator that blocks the activation of tlr4 in a stroke, representing a novel approach to treat ischemic stroke in the acute phase. It could also be administered in patients up to 48 hours after the stroke. AptaTargets targets indications where inflammation causes significant damage through clinical studies and successful preclinical development. The company was founded in 2014 by David Segarra and María Eugenia Zarabozo, with David Segarra serving as the CEO since then. | Director/Miembro de la Junta | 01/06/2018 | - |
Independent Dir/Board Member | 01/06/2018 | - |
Historial de carrera de Mads Dalsgaard
Estadísticas
Internacional
España | 2 |
Operativa
Director/Board Member | 1 |
Independent Dir/Board Member | 1 |
Sectorial
Health Technology | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 1 |
---|---|
AptaTargets SL
![]() AptaTargets SL Pharmaceuticals: MajorHealth Technology AptaTargets SL is a biopharmaceutical company based in Madrid, Spain that focuses on developing therapeutic applications based on aptamer technology. The Spanish company is currently developing aptoll, an immune modulator that blocks the activation of tlr4 in a stroke, representing a novel approach to treat ischemic stroke in the acute phase. It could also be administered in patients up to 48 hours after the stroke. AptaTargets targets indications where inflammation causes significant damage through clinical studies and successful preclinical development. The company was founded in 2014 by David Segarra and María Eugenia Zarabozo, with David Segarra serving as the CEO since then. | Health Technology |
- Bolsa de valores
- Insiders
- Mads Dalsgaard
- Experiencia